90
Participants
Start Date
September 30, 2020
Primary Completion Date
January 20, 2023
Study Completion Date
November 10, 2023
PD patients H&Y=1.5-2 Medications ON
Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
PD patients H&Y=1.5-2 Medications OFF
Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
Healthy age-matched controls
Healthy controls will perform the stop signal task and the go-only task in the same day. The order of administration will be counterbalanced.
PD patients H&Y=3 Medications OFF
Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
PD patients H&Y=3 Medications ON
Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
IRCSS Neuromed Hospital, Pozzilli
Giovanni Mirabella
OTHER